Peptide-based
vaccine delivery can be hampered by rapid
peptidase activity and poor inherent immunogenicity. The self-adjuvanting
lipid core
peptide system (LCP) has been shown to confer improved stability and immunogenicity on
peptide epitopes of group A Streptococcus, Chlamydia, hookworm, and
malaria pathogens. However, various diseases, including
cancer, still require targeted delivery of their
vaccine candidates. For this reason, we have selected two model
peptides (
ovalbumin CD4(+) and/or CD8(+)
T cell epitopes), and incorporated two or four copies of either
epitope into our LCP
vaccine. Optimised glycosylation of
ovalbumin peptides yielded 46 % when microwave-assisted double coupling with 2 eq of
carbohydrate derivative, activated by
N,N-diisopropylethylamine and (O-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, was performed. All
ovalbumin peptides were successfully synthesised and purified in 11-55 % yields by Fmoc- or Boc-chemistry using solid-phase peptide synthesis. The mannosylated
ovalbumin peptides were nontoxic to human erythrocytes in haemolytic assay (<2 %
haemolysis) and showed increased (up to 20-fold) stability in plasma.